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Abstract
Introduction: Kidney transplantation is the treatment of 
choice for patients with end-stage renal disease. Despite 
great progress in surgical aspects and immunosupression 
therapy, long-term graft survival has not been consistent. 
Chronic allograft dysfunction (CAD) remains a major 
cause of late grafts failure. 
Review: CAD is a generic term of all causes of chronic 
renal allograft dysfunction associated with fibrosis. It 
is clinically characterized by a gradual worsening of 
renal function in the presence of arterial hypertension 
and low-grade proteinuria. Histological changes of 
CAD usually precede functional deterioration and 
include interstitial fibrosis/tubular atrophy accompanied 
by vascular changes and glomerulosclerosis. Both 
immunological and non immunological factors can be 
responsible for CAD. Immunological causes include 
chronic active antibody-mediated and T cell-mediated 
rejection. Non immunological factors include brain death 
in the donor, increasing donor age, ischemia-reperfusion 
injury, calcineurin inhibitor nephrotoxicity, hypertension, 
diabetes mellitus, hyperlipidemia, chronic obstruction 
and chronic viral infections. Even if the contributing 
factors to CAD can be identified, not all of them can be 
interrupted prior to and after grafting. Preventive strategies 
include improvements in medical and surgical strategies 
to reduce ischemia-reperfusion injury, strategies to 
minimize acute rejection and strategies aiming for HLA-
matched transplants. Additional measures include tight 
control of blood pressure, proteinuria, lipids and glucose. 
Antivirus treatment, appropriate diet, weight control, 
no smoking and good compliance are also suggested in 
certain settings.  
Conclusion: Evidence-based treatment strategies for 
CAD are lacking, but several prevention and management 
strategies are recommended in clinical practice.
Keywords: Calcineurin Inhibitor Toxicity; Chronic 
Rejection; Ischemia-Reperfusion; Transplantation
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Introduction 
In the past few years there has been a tremendous 
improvement in short-term renal allograft survival but 
no corresponding improvement in the long-term results 
[1]. The latest statistics from the scientific registry of 
transplant recipients (SRTR) for 2008 demonstrate graft 
survival in kidney transplant patients at the first year that 
approach or exceed 90% [2]. These advances are attributed 
to progress in surgical and preservation techniques, better 
use of immunosuppressants and improved tissue typing. 
Unfortunately, the overall gain in long-term kidney graft 
survival rate has not been consistent [3].
Chronic allograft dysfunction (CAD) is the leading cause 
of chronic allograft failure among kidney transplant 
recipients [4] and has a major economic impact. In the 
USA, approximately 4700 patients with failed transplants 
restarted dialysis in 2002, representing about 5% of the 
total number of patients starting dialysis [5].
Definition and clinical diagnosis 
Chronic allograft dysfunction (CAD), previously named 
chronic allograft nephropathy (CAN), is a multifactorial 
process associated with progressive fibrosis and tubular 
atrophy [4]. Through Banff meetings, the definition of 
chronic allograft nephropathy was eliminated as it was 
considered as a generic term of all causes of chronic 
renal allograft dysfunction with fibrosis that inhibited 
the accurate diagnosis of causative pathologies and the 
appropriate therapy [6]. In 2003, Banff classification 
provided a description of morphological changes 
corresponding to different causes of chronic allograft 
injury [6]. These histological changes are generally 
associated with variably reduced renal transplant function, 
although histological changes usually precede functional 
deterioration with hyperfiltration in the remaining 
nephrons [7]. Chronic allograft dysfunction is clinically 
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characterized by a gradual worsening of renal function 
in the presence of arterial hypertension and low-grade 
proteinuria [8]. Proteinuria usually ranges from 0.4 to 2 
g/day but nephrotic proteinuria can be observed in the 
presence of transplant glomerulopathy [9]. In the ALERT 
trial of 2102 long-term kidney transplant recipients, renal 
dysfunction and proteinuria were the two strongest, 
independent risk factors for future graft loss [10]. 
Pathology 
The most commonly reported pathological changes in 
progressive graft failure is chronic interstitial fibrosis and 
tubular atrophy, which is accompanied by vascular changes 
and glomerulosclerosis [11]. Both immunological and 
non-immunological factors may cause chronic allograft 
injury. Underlying pathophysiology can be detected 
histologically by typical glomerular and vascular lesions 
in order to assign a presumed etiology in 60% of chronic 
allograft biopsies [12].With the recognition of the entity 
of chronic antibody-mediated rejection and based on 
new pathologic knowledge, the traditional CAN has been 
divided into three parts: (1) chronic active antibody-
mediated rejection; (2) chronic active T cell-mediated 
rejection; (3) interstitial fibrosis and tubular atrophy with 
no evidence of any specific etiology [6].The diagnosis of 
chronic rejection is usually reserved for cases in which 
there is evidence for a significant role of a host immune 
rejection of the graft, such as the presence of transplant 
glomerulopathy and graft atherosclerosis [13]. The 
presence of C4d deposits in the peritubular capillaries 
also indicates the presence of humoral rejection [14]. 
Reports of cysclosporine A (CsA) and tacrolimus (Tac) 
nephrotoxicity are increasingly common late after 
transplantation [15]. CsA-induced arteriolopathy is 
characterized by vacuolisation and necrosis of smooth 
muscle and endothelial cells with hyaline deposits, 
considered to be the most characteristic marker of CNI 
nephrotoxicity [16]. 
Non-immune chronic graft injury can be also induced 
by chronic obstruction of the ureter and chronic viral 
infections [6]. Chronic obstruction is characterized by 
marked tubular dilation and large Tamm-Horsfall protein 
casts with extravasation into the interstitium, and/or 
lymphatic channels. Chronic polyomavirus infection can 
lead to interstitial fibrosis and tubular atrophy with chronic 
inflammation and viral intranuclear inclusions [6].
Risk factors
Immune-mediated factors
Acute rejection has been recognized as one of the 
most important risk factors for chronic rejection [17].
Numerous studies indicated that acute rejection, the 
time of occurrence, and the number of episodes were all 
associated with an increased risk of graft loss, but less is 
known regarding the severity of rejection [18]. Factors 
contributing to ongoing alloimmune responses include 
breakdown in immunosuppression as a result of patient 
non compliance, therapeutic decisions to minimize 
exposure to complications of immunosuppressive drugs 
or increased HLA mismatches [18]. The deleterious 
long-term impact of cytotoxic anti-HLA antibodies that 
develop after transplantation is another factor supporting 
immunological involvement in chronic rejection [19].
Non-immune factors
The main non-immunologic factors include brain death 
in the donor, ischemia-reperfusion injury, calcineurin 
inhibitor toxicity, hypertension, diabetes mellitus 
(post-transplant or pre-existing), hyperlipidemia and 
Cytomegalovirus (CMV) infection [20].
Donor age
Increasing donor age has been linked with an increased 
risk of CAD [21]. A donor age over 60 years or over 
50 years but with vascular comorbidity reduced 
graft survival [11]. It is now hypothesized that the 
development of chronic allograft injury may be related 
to replicative senescence. The senescence hypothesis is 
based upon cellular exhaustion leading to endothelial and 
epithelial dysfunction and atrophy and thus persistence 
of profibrotic stimuli [22].
Donor source
The results observed with living-unrelated donors are 
better than with cadaveric HLA-matched donors [23]. 
Donor brain death is an independent factor for graft failure 
[24] and is associated with an increased risk of acute 
vascular rejection [25]. Brain death is often associated 
with severe hypotension, an increase in catecholamines, 
electrolytes abnormalities and intracranial hypertension 
that can favor the overproduction of cytokines and 
growth factors leading to overexpression of alloantigens 
on tubular and endothelial cells [26]. 
Delayed graft function  and ischemia-reperfusion 
injury
Delayed graft function  is one of the most important 
independent risk factors for the development of CAD 
[27]. Ischemia-reperfusion injury  can be responsible for 
delayed graft function and can be associated with late 
graft dysfunction particularly when it is combined with 
acute rejection [28]. Tissue ischemia and reperfusion 
represent a complex interplay between biochemical, 
cellular, vascular endothelial and tissue-specific factors 
[29]. Ischemia-reperfusion injury has been shown to 
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cause endothelial injury with consequent upregulation 
of adhesion molecules and infiltration of leucocytes and 
thus create a proinflammatory and profibrotic state within 
the graft [27].
Donor organ quality and comorbidity
Most donors die from cerebrovascular events, which are 
frequently caused by underlying hypertension, diabetes 
and/or atherosclerosis that may also involve the kidney 
[30]. Donor diabetes mellitus, even lasting more than 
10 years, is not necessary an overwhelming risk factor 
for graft and patient survival [31]. On the other hand, 
hypertension is a significant independent risk factor for 
graft survival, especially if it lasts for more than 10 years 
[32].
Calcineurin inhibitors (CNI) nephrotoxicity
Reports of cysclosporine A  and tacrolimus nephrotoxicity 
are increasingly common late after transplantation [33]. 
Both cyclosporine and tacrolimus can cause renal and 
systemic vasoconstriction, through increased release of 
endothelin-1, activation of the renin-angiotension system, 
increased production of thromboxane A2, and decreased 
production of vasodilators such as nitric oxide and 
prostacyclin [34]. At renal biopsy, calcineurin inhibitor 
nephrotoxicity is mainly expressed as progressive 
arteriolar hyalinosis and downstream glomerulosclerosis 
[11].
Cytomegalovirus (CMV) infection
CMV-seronegative recipients of seronegative grafts have 
a 10% higher graft survival rate than those receiving 
seropositive grafts [18]. CMV disease is frequent after 
transplantation and determines changes in immune cell 
function favoring acute rejection [35]. Chronic rejection 
is also accelerated by CMV infection which is associated 
with upregulation of TGFβ and platelet derived growth 
factor (PDGF) in endothelial cells and connective tissue 
growth factor within fibroblasts [36].
Immunology of chronic allograft injury
Chronic allograft injury is an active procedure that is 
closely related to immunoreactivity [37]. The pathogenesis 
of chronic allograft injury appears to be a complex 
network of immunological, metabolic, and hemodynamic 
changes in renal allograft [38]. There is evidence to show 
that CD4 + and CD8 + T cells play roles in recipients 
with chronic allograft injury [37]. In the initial phases 
of the transplantation procedure, during ischemia-
reperfusion injury, CD4 + T cells may be key mediators 
of the resultant subacute inflammatory response [39]. 
CD4 + T cells produce a variety of cytokines that result 
not only in the amplification of the immune response in 
other cells but also act in an autocrine fashion as well. 
Infiltrating inflammatory cells (macrophages, natural 
killer cells, neutrophils) also promote the process of CAN 
by secreting a variety of cytokines and growth factors for 
local damage [39]. Allogeneic differences between donor 
and host lead to a persistence of graft-infiltrating cells, 
including T cells, B cells, and macrophages, accompanied 
by a proliferative response, mediated by chemokines, 
cytokines, and growth factors [41].  
Humoral immunity plays also a role in CAN, the humoral 
responses can be directed against HLA or non-HLA 
antigens of the graft [37]. Renal transplant recipients 
with anti-HLA antibodies were 5 to 6 times more 
likely to develop chronic rejection and lose their grafts 
[42]. Peritubular capillary deposition of C4d reflects 
complement activation via the classical pathway and 
represents a trace of the remaining alloantibodies [43]. 
C4d is a suitable marker of acute humoral rejection [44], 
but it is also documented in late renal allograft biopsies 
with chronic rejection [43]. The endothelial cells are the 
first target of alloreaction [37].  Apoptosis of endothelium 
leads to a series of events that culminate, including 
mononuclear leucocyte recruitment, vascular smooth 
muscle cell proliferation, neointima formation, and 
abnormal vascular remodeling [45]. Emerging evidence 
suggests that epithelial-to-mesenchymal transition 
(EMT) is an important event in chronic allograft tubular 
atrophy/interstitial fibrosis [46]. During the EMT 
process, the tubular epithelial cells lose the epithelial 
cell characteristics, gradually acquire mesenchymal cell 
characteristics and finally transdifferentiate towards 
fibroblasts, resulting in interstitial fibrosis [37].  
Preventive measures
Even if the contributing factors to CAD can be identified, 
not all of them can be interrupted prior to and after 
grafting [37]. Improvements in medical and surgical 
strategies reduced the incidence of delayed graft function 
which is a key factor for CAD [47]. Most programs 
strive to minimize acute rejection rates based on the 
understanding that both clinical and subclinical rejections 
are  major factors for the development of interstitial 
fibrosis and tubular atrophy [48]. Allocation strategies 
primarily aim for HLA-matched transplants that have an 
established superior long-term outcome compared with 
HLA-mismatched grafts [49].
Additional preventive measures include the pre-transplant 
identification of sensitized patients and pre-treatment of 
sensitized recipients, because of the strong association 
between pre-sensitization and development of CAN 
or humoral-driven chronic rejection [14]. Various 
modalities have been used for pre-treatment of sensitized 
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patients, including either plasmaspheresis combined with 
intravenous immunoglobulins or rituximab [50]. After 
transplantation, a sufficient level of immunosuppression 
is definitely required to prevent the onset of acute 
rejection [37].  
Some investigators reported that, in the long term, 
practically all cyclosporine A-treated transplant patients 
showed histologic signs of nephrotoxicity, but in spite 
of this the 10-year kidney graft survival was 95% 
[15]. Three main protocols have been investigated to 
prevent toxicity  of calcineurin-inhibitors (CNI): CNI 
minimization, CNI withdrawal and complete avoidance 
[51]. Reduction and possible withdrawal of CNI with 
either the addition or continuation of mycophenolate 
mofetil slowed the rate of loss of renal function in 
patients with CAN [52]. A CNI-free immunosuppression 
based on sirolimus, mycophenolate mofetil and steroids 
appeared to be effective but the available studies have 
only a short follow-up [53]. 
Besides optimal immunosuppression, prevention of 
premature graft failure requires a multifactorial approach 
aiming at early and tight control of blood pressure, 
proteinuria, lipids, glucose and weight [54]. Significant 
reduction in proteinuria has been reported as a beneficial 
effect of angiotensin-converting enzyme inhibitors 
(ACEI) and angiotensin II receptor antagonists in clinical 
transplantation [37]. The treatment of hyperlipidemia 
and hypertension is also warranted to prevent both 
progressive graft dysfunction and cardiovascular 
disease [55]. Antivirus treatment, diet, weight control, 
no smoking and good compliance are also suggested in 
certain settings [37].  
Conclusion
CAD remains one of the major causes of chronic graft 
loss. The etiology of CAD includes both immune and 
non-immune causes. To date, evidence-based treatment 
strategies for CAD are lacking, but several prevention 
and management strategies are recommended in clinical 
practice.
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